• About Us
  • Science
    • Vaccines
    • Antibodies
  • Our Pipeline
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Company Profile
    • Advisors
    • Corporate Governance
    • 2024 Capital Raise
  • Resources
    • News
    • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Partnership with NHS Cancer Vaccine Launch Pad Enabling Fast-Tracked Access for Melanoma Patients

by chantal | Apr 14, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell to Present Clinical Data from the Ongoing Phase 2 SCOPE Trial of SCIB1 at 2025 AACR Annual Meeting

by chantal | Apr 1, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Issue of share options

by chantal | Feb 20, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell to present translational data from the Phase 2 ongoing SCOPE trial of SCIB1 at the 2025 AACR IO conference

by chantal | Feb 17, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Interim Results for the six months ended 31 October 2024

by chantal | Jan 30, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Notice of Interim Results

by chantal | Jan 23, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries

Recent Posts

  • Investor Update: 24 April 2025
  • Scancell’s new partnership with the NHS Vaccine Launch Pad (CLVP) March 2025
  • Partnership with NHS Cancer Vaccine Launch Pad Enabling Fast-Tracked Access for Melanoma Patients
  • Scancell to Present Clinical Data from the Ongoing Phase 2 SCOPE Trial of SCIB1 at 2025 AACR Annual Meeting
  • AACR 10 (American Association for Cancer Research), February 2025, Los Angeles, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

VACCINES

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2025 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy